Venous ulcer: What is new?

Plastic and Reconstructive Surgery

Volumn 127, Issue SUPPL. 1 S, 2011, Pages

  Raffetto, Joseph D ^a   Marston, William A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC DISEASE; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; VARICOSIS;

CHRONIC DISEASE; HUMANS; VARICOSE ULCER;

EID: 78651263904     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181fcaff2     Document Type: Article

References (58)

1. Nicolaides AN, Hussein MK, Szendro G, Christopoulos D, Vasdekis S, Clarke H. The relation of venous ulceration with ambulatory venous pressure measurements. J Vasc Surg. 1993; 17:414-419.
2. Leu HJ, Wenner A, Spycher MA. Erythrocyte diapedesis in venous stasis syndrome. (Electron microscopic examinations). Vasa 1981;10:17-23.
3. Zamboni P, Scapoli G, Lanzara V, et al. Serum iron and matrix metalloproteinase-9 variations in limbs affected by chronic venous disease and venous leg ulcers. Dermatol Surg. 2005;31:644-649.
4. Wilkinson LS, Bunker C, Edwards JC, Scurr JH, Smith PD. Leukocytes: Their role in the etiopathogenesis of skin damage in venous disease. J Vasc Surg. 1993;17:669-675.
5. Pappas PJ, DeFouw DO, Venezio LM, et al. Morphometric assessment of the dermal microcirculation in patients with chronic venous insufficiency. J Vasc Surg. 1997;26:784-795.
6. Thomas PR, Nash GB, Dormandy JA. White cell accumulation in dependent legs of patients with venous hypertension: A possible mechanism for trophic changes in the skin. BMJ (Clin Res Ed.) 1988;296:1693-1695.
7. Scott HJ, Coleridge Smith PD, Scurr JH. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. Br J Surg. 1991;78:210-211.
8. Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol. 1995;132:79-85.
9. Pappas PJ, You R, Rameshwar P, et al. Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-beta1 gene expression and protein production. J Vasc Surg. 1999;30:1129-1145.
10. Bergan JJ. Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg. Angiology 2005;56(Suppl 1):S21-S24.
11. Nicolaides AN. From symptoms to leg edema: Efficacy of Daflon 500 mg. Angiology 2003;54:S33-S44.
12. Vanscheidt W, Rabe E, Naser-Hijazi B, et al. The efficacy and safety of coumarin-troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: A double blind placebo- controlled randomized study. Vasa 2002;31:185-190.
13. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: A meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005;30:198-208.
14. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res. 2003;92:827-839.
15. Raffetto JD, Khalil RA. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol. 2008;6:158-172.
16. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993;101:64-68.
17. Harris IR, Yee KC, Walters CE, et al. Cytokine and protease levels in healing and non-healing chronic venous leg ulcers. Exp Dermatol. 1995;4:342-349.
18. Weckroth M, Vaheri A, Lauharanta J, Sorsa T, Konttinen YT. Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J Invest Dermatol. 1996;106:1119-1124.
19. Cook H, Stephens P, Davies KJ, Thomas DW. Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity. J Invest Dermatol. 2000;115:225-233.
20. Meyer FJ, Burnand KG, Abisi S, Tekoppele JM, van Els B, Smith A. Effect of collagen turnover and matrix metalloproteinase activity on healing of venous leg ulcers. Br J Surg. 2008;95:319-325.
21. Norgauer J, Hildenbrand T, Idzko M, et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol. 2002;147:1180-1186.
22. Mwaura B, Mahendran B, Hynes N, et al. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg. 2006; 31:306-310.
23. Schmutz JL, Meaume S, Fays S, et al. Evaluation of the nanooligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: Results of a randomised, controlled trial. Int Wound J. 2008;5:172-182.
24. Smeets R, Ulrich D, Unglaub F, Wöltje M, Pallua N. Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. Int Wound J. 2008;5:195-203.
25. Campisi J. The biology of replicative senescence. Eur J Cancer 1997;33:703-709.
26. Raffetto JD, Leverkus M, Park HY, Menzoian JO. Synopsis on cellular senescence and apoptosis. J Vasc Surg. 2001;34:173-177.
27. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogenactivated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol Rev. 1999;79:143-180.
28. Seidman C, Raffetto JD, Overman KC, Menzoian JO. Venous ulcer fibroblasts respond to basic fibroblast growth factor at the cell cycle protein level. Ann Vasc Surg. 2006;20:376-380.
29. Kyriakis JM, Avruch J. Sounding the alarm: Protein kinase cascades activated by stress and inflammation. J Biol Chem. 1996;271:24313-24316.
30. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998;31:152-161.
31. Raffetto JD, Vasquez R, Goodwin DG, Menzoian JO. Mitogen activated protein kinase pathway regulates cell proliferation in venous ulcer fibroblasts. Vasc Endovasc Surg. 2006;40:59-66.
32. Seah CC, Phillips TJ, Howard CE, et al. Chronic wound fluid suppresses proliferation of dermal fibroblasts through a Rasmediated signaling pathway. J Invest Dermatol. 2005;124:466-474.
33. Pappas PJ, Lal BK, Ohara N, Saito S, Zapiach L, Durán WN. Regulation of matrix contraction in chronic venous disease. Eur J Vasc Endovasc Surg. 2009;38:518-529.
34. Raffetto JD, Gram CH, Overman KC, Menzoian JO. Mitogen activated protein kinase p38 pathway in venous ulcer fibroblasts. Vasc Endovasc Surg. 2008;42:367-374.
35. Margolis DJ, Cromblehome T, Herlyn M, et al. Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb compression bandage for the treatment of venous leg ulcer. Trial A. Hum Gene Ther. 2004;15:1003-1019.
36. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000;8:13-25.
37. Lal BK, Saito S, Pappas PJ, et al. Altered proliferative responses of dermal fibroblasts to TGF-beta1 may contribute to chronic venous stasis ulcer. J Vasc Surg. 2003;37:1285-1293.
38. Stanley AC, Park HY, Phillips TJ, Russakovsky V, Menzoian JO. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg. 1997;26:994-1001.
39. Mendez MV, Raffetto JD, Phillips T, Menzoian JO, Park HY. The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer wound fluid: A potential mechanism for senescence in venous ulcers. J Vasc Surg. 1999;30:734-743.
40. Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications 2006;20:329-335.
41. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137:822-827.
42. Beidler SK, Douillet CD, Berndt DF, Keagy BA, Rich PB, Marston WA. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. J Vasc Surg. 2009;49:1013-1020.
43. Gohel MS, Windhaber RA, Tarlton JF, Whyman MR, Poskitt KR. The relationship between cytokine concentrations and wound healing in chronic venous ulceration. J Vasc Surg. 2008;48:1272-1277.
44. Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol. 1992;18:604-606.
45. Stacey MC, Mata SD, Trengove NJ, Mather CA. Randomized double-blind placebo controlled trial of topical autologous platelet lysate in venous ulcer healing. Eur J Vasc Endovasc Surg. 2000;20:296-301.
46. Robson MC, Phillips TJ, Falanga V, et al. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen. 2001;9:347-352.
47. Drinkwater SL, Burnand KG, Ding R, Smith A. Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. J Vasc Surg. 2003;38:1106-1112.
48. Cowin AJ, Hatzirodos N, Holding CA, et al. Effect of healing on the expression of transforming growth factor beta(s) and their receptors in chronic venous leg ulcers. J Invest Dermatol. 2001;117:1282-1289.
49. Cullum N, Nelson EA, Fletcher AW, Sheldon TA. Compression for venous leg ulcers (Cochrane Review). In: The Cochrane Library. Oxford: Update Software; 2001:575-581.
50. Marston WA, Carlin RE, Passman MA, Farber MA, Keagy BA. Healing rates and cost efficacy of outpatient compression treatment for leg ulcers associated with venous insufficiency. J Vasc Surg. 1999;30:491-498.
51. Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers. Cochrane Database Syst Rev. 2006;3:CD001103.
52. Michaels JA, Campbell B, King B, Palfreyman SJ, Shackley P, Stevenson M. Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial). Br J Surg. 2009;96: 1147-1156.
53. Gohel MS, Barwell JR, Taylor M, et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): Randomised controlled trial. BMJ. 2007;335:83.
54. Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7:201-207.
55. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D; OASIS Venus Ulcer Study Group. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: A randomized clinical trial. J Vasc Surg. 2005;41:837-843.
56. Robson MC, Cooper DM, Aslam R, et al. Guidelines for the treatment of venous ulcers. Wound Repair Regen. 2006;14: 649-662.
57. Neglén P, Hollis KC, Olivier J, Raju S. Stenting of the venous outflow in chronic venous disease: Long-term stent-related outcome, clinical, and hemodynamic result. J Vasc Surg. 2007; 46:979-990.
58. Darvell KA, Sam RC, Adam DJ, Silverman SH, Fegan CD, Bradbury AW. Higher prevalence of thrombophilia in patients with varicose veins and venous ulcers than controls. J Vasc Surg. 2009;49:1235-1241.